Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 11,000
- Avg volume
- —
- Day's range
- $17.36 – $17.36
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the distribution of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, Specialty Drug Contract Distribution, and Healthcare Related Services. The Pharmaceutical Distribution Business segment purchases ethic...
Show more
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the distribution of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, Specialty Drug Contract Distribution, and Healthcare Related Services. The Pharmaceutical Distribution Business segment purchases ethical drugs, diagnostic agents, medical equipment, medical materials, and medical food products, as well as pharmaceutical and medical equipment manufacturers, and supplies medical institutions, and insurance pharmacies. The Healthcare Product Development segment offers ethical drugs, diagnostic reagents, and medical devices and materials. The Community Healthcare and Nursing Care Support segment provides a range of pharmacy and nursing care services. The Healthcare Related Services segment offers contract distribution for manufacturers and contract distribution of orphan drugs. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
- Industry
- Medical Distribution
- Sector
- Healthcare
- Phone
- 81 52 961 2331
- Website
- https://www.suzuken.co.jp
- Address
- 8 Higashi Kataha-machi, Higashi-ku, Nagoya, Japan
Latest news
No headlines yet.